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Background: Though treatments for head and neck cancer have improved in recent years, significant variation
persists in the delivery of surgery, radiation therapy, and systemic therapy to patients throughout the United States.
Body: In this review, we explore the current evidence regarding radiation therapy utilization inequities across the
spectra of race, socioeconomic status, and age. We also discuss hypothesized mechanisms for how non-clinical
factors may influence shared clinical decisions between patients and providers. Finally, we suggest future directions
for research in treatment disparities.
Conclusions: Radiation therapy continues to be delivered inequitably among certain subpopulations with head
and neck cancer and other cancers. More research into the drivers of these disparities and interventions designed
to address them are necessary.
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Head and neck cancerBackground
The multidisciplinary management of head and neck
cancer (HNC) has advanced rapidly in recent years. So-
phisticated conformal radiation therapy techniques like
intensity-modulated radiation therapy and proton beam
radiation therapy, surgical approaches like transoral ro-
botic surgery, and targeted biologic agents like cetuxi-
mab have been increasingly utilized in combination with
each other to maximize tumor control while minimizing
toxicities. In the setting of the rising prevalence of HPV-
associated HNC, much research is devoted to optimizing
management strategies for every patient subgroup.
However, not all patients may have equal access to
such advancements in cancer therapy, specifically radi-
ation therapy. In this review, we explore the current evi-
dence demonstrating radiation therapy utilization
inequities across the spectra of race, socioeconomic sta-
tus, and age. We first focus on HNC before expanding
to evidence from other more common malignancies in* Correspondence: roy.decker@yale.edu
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pothesized mechanisms for how sociodemographic fac-
tors may influence shared clinical decisions between
patients and providers. Finally, we suggest potential fu-
ture directions for research and interventions in this
area.
Main text
Evidence of radiation therapy delivery disparities in HNC
One of the most heavily studied subjects in cancer treat-
ment delivery disparity research has revolved around race.
Two recent manuscripts have indicated differences in de-
finitive treatment receipt by racial group for patients with
HNC. First, Mahal et al. used Surveillance, Epidemiology,
and End Results (SEER) database to determine that
African-American patients with non-metastatic HNC
were less likely to receive definitive treatment (surgery, ra-
diation therapy, or both per National Comprehensive
Cancer Network guidelines) than those who were not
African-American (adjusted odds ratio 0.63, 95 % confi-
dence interval 0.55–0.72) [1]. These results persisted in
subsets of patients with cancers of the oral cavity, hypo-
pharynx, nasopharynx, and larynx, but not oropharynx. Inle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Summary of major themes associated with disparities
in radiation therapy delivery
Disparity Theme Evidence for Disparities in Head &
Neck Cancer
1) Underutilization of Definitive
Radiation Therapy and/or Surgery
Race [1, 2]; Insurance [3]
2) Delayed Time from Diagnosis
to Radiation Therapy Initiation
Race, Ethnicity, Insurance, Age,
Income, Education [6]





4) Limited Access to High-Volume
Radiation Therapy Providers
Race [13]; Insurance [14]
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used as a proxy for comorbidity in multivariable logistic
regression, the results did not change significantly. Sec-
ond, Subramanian et al. also examined the effect of race
on treatment receipt among Medicaid patients in Califor-
nia and Georgia with HNC [2]. After adjustment for
demographics, stage at diagnosis, and tumor site, black
race was not associated with differences in radiotherapy
utilization, though it was associated with a lower likeli-
hood of receiving surgery.
Medicaid insurance and lack of insurance have also been
associated with disparities in treatment delivery in HNC.
Inverso et al. reported that after adjustment for patient
demographic data, socioeconomic factors, and tumor
characteristics, uninsured patients with nonmetastatic
HNC in the SEER database were more likely to not receive
definitive treatment than those with any type of insurance
(adjusted odds ratio 1.64, 95 % CI 1.37–1.96) [3]. Sensitiv-
ity analyses further categorizing insurance status found
that patients with no insurance or Medicaid insurance
were more likely to not receive definitive treatment than
those with private insurance.
Appropriate receipt vs. inappropriate omission of radi-
ation therapy is not the only factor affecting optimal
treatment delivery. Prolonged time from cancer diagno-
sis to treatment initiation may have an impact on tumor
control and mortality [4–6]. Murphy et al. noted signifi-
cant variation in time to treatment initiation by race,
Hispanic ethnicity, insurance status, zip-code-level in-
come, zip-code-level education, and age among patients
with HNC in the NCDB [6].
Another source of disparities in high-quality radiation
therapy delivery may be access to advanced techniques
like intensity-modulated radiation therapy or proton
beam radiation therapy. Both modalities have been asso-
ciated with significant improvements in toxicities and
quality-of-life [7–9], with one retrospective study even
suggesting a cancer-specific survival benefit to intensity-
modulated radiation therapy over 3D-conformal radi-
ation therapy [10]. Using the SEER-Medicare linked
database, Sher et al. found that patients living in a cen-
sus tract with higher median income were significantly
more likely to be treated with intensity-modulated radi-
ation therapy [11]. No difference in intensity-modulated
radiation therapy utilization by race, sex, or age was
noted in any of the three published SEER-Medicare
studies on this subject [10–12]. The value of proton
beam radiation therapy for HNC is currently under
active investigation. Though there are no publications
available regarding disparities in proton beam radiation
therapy utilization in HNC to our knowledge, this is po-
tentially a promising field of study in the future.
An increasing amount of data supports the hypoth-
esis that radiation therapy by high-volume providers isassociated with improved outcomes in HNC [13, 14]
and multiple non-HNC malignancies like lung, cer-
vical, and prostate cancers [15–18]. In HNC, two re-
cent large national database analyses have noted
disparities in access to high-volume providers, which
may serve as another proxy for access to high-quality
cancer care. First, Boero et al. found that in the SEER-
Medicare linked database, white patients receiving 3D-
conformal radiation therapy and intensity-modulated
radiation therapy for HNC were more significantly
likely to be treated by high-volume radiation oncolo-
gists than non-white patients [13]. Second, Wuthrick
et al. reported that patients with private insurance
were more likely to receive HNC treatment at high-
accruing facilities into Radiation Therapy Oncology
Group trials than those without private insurance [14].
Table 1 summarizes the primary themes of the dispar-
ities observed in HNC.
Evidence of radiation therapy delivery disparities in non-
HNC malignancies
It should be noted that racial, socioeconomic, and age dis-
parities in radiation therapy delivery are well-documented
in non-HNC cancers, such as prostate cancer [19]. Based
on SEER data, African-American patients were less likely to
receive curative-intent therapy (adjusted odds ratio 0.82,
95 % confidence interval 0.79–0.86), especially among pa-
tients with NCCN high-risk disease (adjusted odds ratio
0.60, 95 % confidence interval 0.56–0.64) [20]. Filipino men
were also less likely to receive definitive treatment in local-
ized prostate cancer in a SEER study of Asian-Americans
[21]. Among patients receiving definitive therapy, African-
American men are more likely to receive radiation therapy
but less likely to undergo surgery [20, 22].
In addition, Bledsoe et al. examined the effect of insur-
ance status on treatment selection among nonelderly pa-
tients with prostate cancer in the NCDB [23]. Even after
adjustment for race and other sociodemographic and
clinical factors, Medicaid patients were less than half as
likely to receive minimally invasive surgery and instead
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radiation therapy compared to patients with private in-
surance. There were no differences in minimally invasive
surgery and external beam radiation therapy utilization
rates between patients with Medicaid insurance com-
pared to no insurance at all. For prostate cancer patients
who do receive radiation therapy in the National Cancer
Data Base (NCDB) database, black and Hispanic patients
were found to be significantly less likely to receive pro-
ton beam radiation therapy than white patients [24].
There is also evidence of disparities in treatment deliv-
ery beyond external beam radiation therapy in HNC and
prostate cancer. Grant et al. examined patients in the
SEER database to determine the association between in-
surance status and brachytherapy receipt [25]. The study
showed that patients who received radiation therapy de-
finitively for prostate and cervical cancer or postopera-
tively for breast cancer were less likely to receive
brachytherapy if they had Medicaid coverage (odds ratio
0.57, 95 % CI 0.53–0.61) or no insurance coverage (odds
ratio 0.50, 95 % CI 0.45–0.56) compared to those with
non-Medicaid insurance. A SEER study of 3,851 black
patients and 44,010 white patients with rectal cancer
showed that black patients were significantly more likely
to receive no radiation therapy for stage II to III disease
(adjusted odds ratio 1.30, 95 % confidence interval 1.15–
1.47) [26]. Older patients were less likely to receive the
standard-of-care combination of radiation therapy with
fluorouracil-based chemotherapy among 1,807 Medicare
beneficiaries with stage II to III rectal cancer in the
SEER-Medicare database [27]. Similar trends were noted
in stage I to II breast cancer, as older women were less
likely to receive optimal local treatment with radiation
therapy and surgery [28, 29].
Potential mechanisms
We have now shown that sociodemographic factors may
play a significant role in contributing to gaps in radiation
therapy delivery. Disparities in radiation therapy delivery
may be at least partially related to differences in referral
patterns to radiation oncologists. The lung cancer litera-
ture has studied this feature most extensively. Goulart
et al. analyzed data from 28,977 patients with stage III
and IV non-small cell lung cancer diagnosed in 2000–
2005 from the SEER-Medicare database linked with the
American Medical Association Masterfile database [30].
On multivariable analysis, older age, black race, and fe-
male sex were associated with a lower likelihood of see-
ing all cancer specialists (medical oncologists, radiation
oncologists, and thoracic or general surgeons). Seeing all
three types of cancer specialists was predictive of a sig-
nificantly higher likelihood of receiving National Com-
prehensive Cancer Network (NCCN) guideline-based
therapies. Although these numbers were not explicitlyreported in the manuscript, our calculations reveal that
the likelihood of receiving guideline-based therapies for
patients with vs. without radiation oncologist referral
was 64.1 % vs. 20.1 % for stage IIIA disease and 56.3 %
vs. 6.3 % for stage IIIB disease.
Australian data by Vinod et al. also show disparities in
radiation oncologist referrals [31]. Based on question-
naire data from diagnosing and treating clinicians for
1,812 lung cancer patients from New South Wales, the
authors found significant underutilization of curative-
intent radiation therapy to the primary site (20 % actual
vs. 50 % optimal), especially in patients with limited-
stage small cell lung cancer (46 % actual vs. 94 % opti-
mal). Older patients were again less likely to be referred
to radiation oncologists, as were patients who lived in
areas that were not highly accessible by distance to
major service centers based on the Accessibility and Re-
moteness Index for Australia. Patient sex did not impact
referral patterns, while race and income level were not
analyzed in this study.
Other reasons for disparities in radiation therapy deliv-
ery can be considered within a framework involving
three broad categories: poverty, culture, and social in-
justice [32]. Barriers related to poverty and low socio-
economic status include the lack of a primary care
physician, who would conduct screening and diagnostic
follow-up; limited access to healthcare based on geo-
graphical inconveniences; competing survival priorities
such as obtaining food, shelter, and safety; medical co-
morbidities; lack of adequate health insurance; lack of
information and knowledge; and risk-promoting life-
styles, like poor nutrition and physical inactivity [33, 34].
Cultural factors, which reflect a set of learned and
shared beliefs, values, traditions, world views, communi-
cation styles, and behavior common to a particular social
group, can also play a large role in racial disparities in
treatment delivery. Factors like spirituality, perceived
susceptibility to cancer, cultural beliefs about cancer, and
medical mistrust can be major barriers for certain cul-
tural groups [33]. For instance, black women often con-
sider themselves at lower risk for developing breast
cancer than white women, even among those with a
family history of breast cancer, which may translate into
low perceived need for mammography or delays in seek-
ing treatment for a breast abnormality [35]. There may
also be a more fatalistic attitude regarding breast cancer
treatment, less confidence in Western medicine, more
confidence that spirituality and divine intervention are
more effective in promoting cure, and a cultural norm
against discussing breast cancer among certain cultural
groups [36–39]. Traditional practices like Ayurvedic and
Traditional Chinese medicine or Mexican herbal mix-
tures may or may not have beneficial or harmful effects
on cancer treatment, especially regarding interactions
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closure of this information by patients may be hindered
by fear of receiving judgmental or dismissive comments
from oncology providers, thereby excluding the potential
of communication about these issues [34]. Patient-
provider communication is also critical when addressing
medical truth-telling at the end-of-life in certain family
and community-centered societies, where practices of
nondisclosure often persist due to cancer-related social
stigma [34].
Social injustice, including factors like racial prejudice
and discrimination, may also factor into racial dispar-
ities, but this relationship does not appear to have been
as well studied as socioeconomic status or culture [32].
Provider perceptions of racial minority patients may
affect quality of care, as physicians rated black patients
with coronary artery disease as less educated and less
likely to comply with treatment, even after adjusting for
socioeconomic status [40]. In addition, black women
were more likely to report a lack of physician recom-
mendation as a reason for not undergoing mammog-
raphy [41]. While it is certainly debatable whether or
not these findings due to racial prejudice or other fac-
tors, perceived racial discrimination by patients may also
play a role in differences in cancer incidence as well as
treatment and satisfaction with care [42]. For instance,
black women younger than 50 years who reported
higher levels of racial discrimination in “everyday” expe-
riences were at greater risk of subsequently developing
breast cancer, since perceived racism could act as a
chronic stressor that alters immune functioning and/or
endogenous hormone levels [43].
Conclusions
Radiation therapy continues to be delivered inequitably
among certain subpopulations with head and neck can-
cer and other cancers. Ultimately, it appears that the key
to future research on treatment disparities in cancer lies
upon disentangling apparent effects of race, poverty, age,
education, and discrimination. It is also important to im-
prove the measurement accuracy of specific indicators of
socioeconomic status beyond broad measures of house-
hold income in a given zip code or census tract. In order
to close these gaps, we must evaluate various communi-
cation practices in the way treatments are decided and
patient autonomy is upheld.
We must also venture well beyond medical care itself.
Patient education regarding high-risk behavior like
smoking, obesity, and environmental hazards; programs
facilitating travel to healthcare organizations; legislative
action to improve access to healthcare; and general im-
provements in housing, schooling, and neighborhood
safety must all be addressed before disparities caused
by these factors can be minimized. However, it is stillunclear if and how interventions addressing these areas
could make a measurable difference.
With improving awareness of the complexity of this
problem, there will hopefully be a growth in research in-
frastructure capturing this necessary data. More sophis-
ticated analyses that account for these covariates will
help clarify the most critical determinants of these dis-
parities and to create and evaluate interventions on indi-
vidual, locoregional, national, and international levels to
address and eliminate them.
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